Literature DB >> 29173266

Case: Testicular oligometastasis from prostate cancer - Report of rare isolated recurrence after radiotherapy and intermittent androgen-deprivation therapy.

Chan-Kyung J Cho1,2, Samantha Sigurdson1, Christopher M Davidson3, Michael Leveridge4, Aamer Mahmud1,2.   

Abstract

Entities:  

Year:  2017        PMID： 29173266      PMCID： PMC5783705          DOI： 10.5489/cuaj.4524

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  13 in total

1.  Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients.

Authors:  L Bubendorf; A Schöpfer; U Wagner; G Sauter; H Moch; N Willi; T C Gasser; M J Mihatsch
Journal:  Hum Pathol       Date:  2000-05       Impact factor: 3.466

Review 2.  Evolving Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer.

Authors:  Jessica M Clement; Christopher J Sweeney
Journal:  J Oncol Pract       Date:  2017-01-03       Impact factor: 3.840

Review 3.  [Testicular metastasis of a metachronous small cell neuroendocrinic prostate cancer after anti-hormonal therapy of a prostatic adenocarcinoma. Case report and literature review].

Authors:  A Schneider; A Kollias; J Woziwodzki; G Stauch
Journal:  Urologe A       Date:  2006-01       Impact factor: 0.639

4.  Intermittent androgen suppression for rising PSA level after radiotherapy.

Authors:  Juanita M Crook; Christopher J O'Callaghan; Graeme Duncan; David P Dearnaley; Celestia S Higano; Eric M Horwitz; Eliot Frymire; Shawn Malone; Joseph Chin; Abdenour Nabid; Padraig Warde; Thomas Corbett; Steve Angyalfi; S Larry Goldenberg; Mary K Gospodarowicz; Fred Saad; John P Logue; Emma Hall; Paul F Schellhammer; Keyue Ding; Laurence Klotz
Journal:  N Engl J Med       Date:  2012-09-06       Impact factor: 91.245

Review 5.  Intermittent androgen suppression for prostate cancer.

Authors:  Nicholas C Buchan; S Larry Goldenberg
Journal:  Nat Rev Urol       Date:  2010-09-14       Impact factor: 14.432

Review 6.  Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations.

Authors:  Jeffrey J Tosoian; Michael A Gorin; Ashley E Ross; Kenneth J Pienta; Phuoc T Tran; Edward M Schaeffer
Journal:  Nat Rev Urol       Date:  2016-10-11       Impact factor: 14.432

7.  Testicular metastases: a poor prognostic factor in patients with advanced prostate cancer.

Authors:  Fernando Korkes; Renato Gasperini; Karen Levy Korkes; Deusdedit Cortez Vieira Silva Neto; Marilia Germanos Castro
Journal:  World J Urol       Date:  2008-09-02       Impact factor: 4.226

Review 8.  Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature.

Authors:  Per-Anders Abrahamsson
Journal:  Eur Urol       Date:  2009-08-07       Impact factor: 20.096

9.  Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy.

Authors:  M T Schweizer; X C Zhou; H Wang; T Yang; F Shaukat; A W Partin; M A Eisenberger; E S Antonarakis
Journal:  Ann Oncol       Date:  2013-08-14       Impact factor: 32.976

10.  Testicular metastasis of prostate cancer: a case report.

Authors:  Ayumu Kusaka; Takuya Koie; Hayato Yamamoto; Itsuto Hamano; Takahiro Yoneyama; Yasuhiro Hashimoto; Chikara Ohyama; Yuki Tobisawa; Tohru Yoneyama
Journal:  Case Rep Oncol       Date:  2014-09-18
View more
  1 in total

1.  Isolated Testicular Metastasis Diagnosed More than a Decade and a Half Post Primary Treatment for Prostate Cancer.

Authors:  Nassib F Abou Heidar; Gerges Bustros; Jose M El-Asmar; Bassel Zein Sabatto; Jad A Degheili
Journal:  Case Rep Oncol Med       Date:  2019-11-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.